Bio-Rad Laboratories Overview
Get informed when a big investor buys or sells
+ Follow13.45%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for BIO.B is 13.45%. That is above the Healthcare sector average of 13.26%. Investors often review this figure alongside Bio-Rad Laboratories's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, BIO.B currently prints 13.45% for ROE, while the sector average sits near 13.26%. That is roughly 1.4% above the sector mean. Large gaps often invite a closer look at Bio-Rad Laboratories's growth, margins, and balance sheet.
Return on Equity shows how effectively Bio-Rad Laboratories converts resources into returns. At 13.45%, BIO.B may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting BIO.B's ROE (13.45%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Bio-Rad Laboratories's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
